In conclusion, we found that bone-related biomarkers did not associate with future hip fracture risk, with the exceptions of sclerostin and possibly osteocalcin in men, and addition of biomarkers to clinical risk prediction models did not improve or minimally improved prediction of fracture outcomes. This evidence concerns the gene BGLAP and hip fracture.